Skip to main content

Table 1 Baseline characteristics and efficacy data of patient cohort analyzed for BCNU-related side effects

From: Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients

Patient Characteristics  
Patient Sample [n] 163
Age at onset of BCNU therapy [years] (median; range) 44 (17–81)
Sex [male:female; n] 108:55
Karnofsky Performance Score [%] (median; range) 80 (20–100)
Histology [number of patients] (%)
 Glioblastoma WHO grade IV 84 (51,5)
 Oligodendroglioma WHO grade III 30 (18,4)
 Oligoastrocytoma WHO grade III 14 (8,6)
 Astrocytoma WHO grade III 13 (8)
 Oligodendroglioma WHO grade II 12 (7,4)
 Oligoastrocytoma WHO grade II 3 (1,8)
 Astrocytoma WHO grade II 7 (4,3)
Median OS [months]
 WHO grade II tumors 191
 WHO grade III tumors 144
 WHO grade IV tumors 20
Median PFSBCNU [months]
 WHO grade II tumors 85
 WHO grade III tumors 28
 WHO grade IV tumors 7
Death [number of patients] (%)
 WHO grade II tumors 9 (41)
 WHO grade III tumors 37 (65)
 WHO grade IV tumors 82 (98)
Lost to follow up [number of patients] (%)
 WHO grade II tumors 5 (23)
 WHO grade III tumors 13 (23)
 WHO grade IV tumors 1 (1)
Pre-treatment [number of patients] (%)
 Radiotherapy 147 (90)
 Temozolomide 20 (12,2)
 PCV 4 (2,4)
 Methotrexate 2 (1,2)
BCNU – total dose [mg] (median; range) 1662 (300–5200)
BCNU – number of cycles (median; range) 5 (1–16)
BCNU-related side effects [number of patients] (%) 88 (54)
 WHO grade II tumors 18 (82)
 WHO grade III tumors 35 (61)
 WHO grade IV tumors 35 (42)
BCNU – dose reduction to due side effects (%) 48 (29,4)
BCNU – Hospital admission due to side effects (%) 2 (1,2)
Chemotherapy-related deaths (%) 0